Comparative study on the clinical efficacy and safety of the Alrex (0.2% Lotemax) and Patalo (0.1% olopatadine hydrochloride) treatment of seasonal allergic conjunctivitis (SAC)

Trial Profile

Comparative study on the clinical efficacy and safety of the Alrex (0.2% Lotemax) and Patalo (0.1% olopatadine hydrochloride) treatment of seasonal allergic conjunctivitis (SAC)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Loteprednol etabonate (Primary) ; Olopatadine
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top